MX2022012067A - 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad agonista de gpr52. - Google Patents

3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad agonista de gpr52.

Info

Publication number
MX2022012067A
MX2022012067A MX2022012067A MX2022012067A MX2022012067A MX 2022012067 A MX2022012067 A MX 2022012067A MX 2022012067 A MX2022012067 A MX 2022012067A MX 2022012067 A MX2022012067 A MX 2022012067A MX 2022012067 A MX2022012067 A MX 2022012067A
Authority
MX
Mexico
Prior art keywords
phenoxyazetidin
pyrazines
gpr52
substituted
agonistic activity
Prior art date
Application number
MX2022012067A
Other languages
English (en)
Inventor
Kai Gerlach
Marco Ferrara
Yifeng Xiong
Barbara Bertani
Frank Runge
Graeme Semple
Giacomo Fossati
Scott Hobson
Julian Wippich
Uta Friederike Lessel
Ursula Mueller-Vieira
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022012067A publication Critical patent/MX2022012067A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a 3-fenoxiazetidin-1-il-pirazinas sustituidas de la fórmula general (I) que son agonistas de GPR52, útiles en el tratamiento de enfermedades del sistema nervioso central y otras enfermedades. Además, la invención se refiere a 3-fenoxiazetidin-1-il-pirazinas de la fórmula general (I) para su uso como medicamento, composiciones farmacéuticas que comprenden 3-fenoxiazetidin-1-il-pirazinas de la fórmula general (I) y procesos para preparar composiciones farmacéuticas, así como procesos para fabricar los compuestos según la invención.
MX2022012067A 2020-03-30 2021-03-29 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad agonista de gpr52. MX2022012067A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (1)

Publication Number Publication Date
MX2022012067A true MX2022012067A (es) 2022-10-13

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012067A MX2022012067A (es) 2020-03-30 2021-03-29 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad agonista de gpr52.

Country Status (18)

Country Link
US (1) US11780827B2 (es)
EP (1) EP4126850B1 (es)
JP (1) JP2023522307A (es)
KR (1) KR20220161454A (es)
CN (1) CN115697997A (es)
AR (1) AR121675A1 (es)
AU (1) AU2021250303A1 (es)
BR (1) BR112022018996A2 (es)
CA (1) CA3176265A1 (es)
CO (1) CO2022014886A2 (es)
CR (1) CR20220554A (es)
DO (1) DOP2022000203A (es)
EC (1) ECSP22080683A (es)
IL (1) IL296823A (es)
MX (1) MX2022012067A (es)
PE (1) PE20221918A1 (es)
TW (1) TW202204343A (es)
WO (1) WO2021198149A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230131465A1 (en) 2021-09-14 2023-04-27 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
WO2009157196A1 (ja) 2008-06-25 2009-12-30 武田薬品工業株式会社 アミド化合物
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
JPWO2011093352A1 (ja) 2010-01-27 2013-06-06 武田薬品工業株式会社 チアゾール誘導体
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
ES2784316T3 (es) * 2015-04-29 2020-09-24 Arena Pharm Inc 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo
CA2998491A1 (en) * 2015-09-17 2017-03-23 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
CN115697997A (zh) 2023-02-03
US20220356172A1 (en) 2022-11-10
BR112022018996A2 (pt) 2022-11-01
KR20220161454A (ko) 2022-12-06
US11780827B2 (en) 2023-10-10
DOP2022000203A (es) 2022-11-30
EP4126850A1 (en) 2023-02-08
AU2021250303A1 (en) 2022-09-22
ECSP22080683A (es) 2022-11-30
TW202204343A (zh) 2022-02-01
CO2022014886A2 (es) 2022-10-31
IL296823A (en) 2022-11-01
CA3176265A1 (en) 2021-10-07
WO2021198149A1 (en) 2021-10-07
CR20220554A (es) 2023-01-09
JP2023522307A (ja) 2023-05-30
PE20221918A1 (es) 2022-12-29
EP4126850B1 (en) 2024-04-17
AR121675A1 (es) 2022-06-29

Similar Documents

Publication Publication Date Title
JOP20210307A1 (ar) مثبطات جسيم التهابي nlrp3
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2021004707A (es) Nuevos compuestos antihelminticos.
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
PH12018502337A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2022014925A (es) Moduladores de il-17a.
CR20220538A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MX2023012187A (es) Derivados de fosforo como nuevos inhibidores de sos1.
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
MX2021011576A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
CR20220554A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas
MX2023006881A (es) Antagonistas del receptor de adenosina a2a.
MX2022013946A (es) Antagonistas del receptor de adenosina a2a.
MX2022013396A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
PH12021550258A1 (en) Cdk8/19 inhibitors